Market Place
Sourcing Support
Cogent Bio Presents Multiple SUMMIT Posters At AAAAI 2026
10 Feb 2026 //
GLOBENEWSWIRE
Cogent’s Bezuclastinib Combo Gains FDA Breakthrough Status
26 Jan 2026 //
GLOBENEWSWIRE
Cogent Biosciences Files NDA for Bezuclastinib Under RTOR Review
20 Jan 2026 //
GLOBENEWSWIRE
Cogent Biosciences Files NDA for Bezuclastinib Under RTOR
20 Jan 2026 //
GLOBENEWSWIRE
Cogent Biosciences Outlines 2026 Bezuclastinib Milestones
12 Jan 2026 //
GLOBENEWSWIRE
Cogent Submits NDA for Bezuclastinib in NonAdvanced Mastocytosis
30 Dec 2025 //
GLOBENEWSWIRE
Cogent Biosciences Reports Bezuclastinib Success In Advsm Trial
08 Dec 2025 //
GLOBENEWSWIRE
Cogent Biosciences Unveils Complete Bezuclastinib SUMMIT Data
06 Dec 2025 //
GLOBENEWSWIRE
Cogent Eyes FDA Approval After Clearing Another Ph. 3 Hurdle
12 Nov 2025 //
FIERCE BIOTECH
Cogent Biosciences Presents at ASH Meeting
03 Nov 2025 //
GLOBENEWSWIRE
Cogent Bio Reports Q3 2025 Financials And Business Updates
03 Nov 2025 //
GLOBENEWSWIRE
Cogent Biosciences Reveals FDA Breakthrough For Bezuclastinib
20 Oct 2025 //
GLOBENEWSWIRE
Cogent’s Bezuclastinib Hits All Endpoints in SUMMIT Trial
08 Jul 2025 //
GLOBENEWSWIRE
Cogent Hits Primary Endpoint, Building Case for Blueprint Rival
07 Jul 2025 //
FIERCE BIOTECH
Cogent Previews 2025 Goals For Bezuclastinib & Targeted Drugs
13 Jan 2025 //
GLOBENEWSWIRE
Cogent Biosciences Presents Bezuclastinib Data at ASH 2024
05 Nov 2024 //
GLOBENEWSWIRE
Cogent Reports Additional Bezuclastinib Data In NonAdvSM
14 Jun 2024 //
GLOBENEWSWIRE
Cogent Bezuclastinib Peak Lead-In: Gist Phase 3 Positive At Asco
23 May 2024 //
GLOBENEWSWIRE
Cogent Announces Positive Part 1b Data from Trial Evaluating Bezuclastinib
22 Feb 2024 //
GLOBENEWSWIRE
Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvSM
05 Feb 2024 //
GLOBENEWSWIRE
Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib
09 Jan 2024 //
GLOBENEWSWIRE
Cogent Announces Positive Data from Phase 2 APEX Trial Evaluating Bezuclastinib
11 Dec 2023 //
GLOBENEWSWIRE
Cogent Announces Positive Data from Phase 2 Trial Evaluating Bezuclastinib
09 Dec 2023 //
GLOBENEWSWIRE
Cogent Bio Announces Positive Lead-In Data from Ongoing Phase 3 PEAK Trial
03 Jun 2023 //
GLOBENEWSWIRE
Cogent Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial
11 Dec 2022 //
GLOBENEWSWIRE
Cogent Biosciences to Host Investor Webcast to Discuss Clinical Data at ASH
05 Dec 2022 //
BIOSPACE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.